Gut Microbiome May Predict Treatment Side Effects & New T-cell Therapies Aimed at EBV

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads
a news article on how differences in the gut microbiome have been linked to an altered risk of developing low immune cell counts following treatment with Tecfidera.

He also reads a second article reporting that Tevogen Bio has announced plans to develop T-cell therapies that target the Epstein-Barr virus.
===================================
Are you interested in learning more about multiple sclerosis? If so, please visit:
https://multiplesclerosisnewstoday.com/
=====================================
To join in on conversations regarding multiple sclerosis, please visit:
https://multiplesclerosisnewstoday.com/forums/